| |
 John A. Scarlett, M.D., Chief Executive Officer
Dr. Scarlett established Tercica's U.S. operations in May 2002 after serving as Chief Executive Officer of Sensus Drug Development Corporation, another Genentech licensee. He previously co-founded Covance Biotechnology Services and held senior management positions at the North American Clinical Development Organization, Novo Nordisk Pharmaceuticals, Greenwich Pharmaceuticals, and McNeil Pharmaceuticals. Dr. Scarlett graduated with honors from the University of Chicago's Pritzker School of Medicine. He trained in internal medicine at the Hospital of the University of Pennsylvania, and in endocrinology and metabolism at the University of Colorado. |
|
| |
 Richard A. King, President and Chief Operating Officer
Prior to joining the company as Chief Operating Officer in February 2007, Mr. King served as Executive Vice President, Commercial Operations of Kos Pharmaceuticals, Inc. from 2002 to 2006, where he was responsible for sales, marketing, managed care, sales operations, and customer service functions. Prior to his employment at Kos, from 2000 to 2002 Mr. King was Senior Vice President of Commercial Operations at Solvay Pharmaceuticals, and from 1992 to 2000, held various marketing positions at SmithKline Beecham Pharmaceuticals. A native of the United Kingdom, Mr. King began his career in the pharmaceutical industry at Lederle Laboratories, Ltd. He holds a Bachelor of Science degree in Chemical Engineering from the University of Surrey, and an M.B.A. from Manchester Business School. |
|
| |
 Ross G. Clark, Ph.D., Chief Technical Officer and Founder
Dr. Clark founded our predecessor company, Tercica Limited, in New Zealand in 2000 and has held his current post since our U.S. company was formed in 2002. Dr. Clark was previously a co-founder of ViaLactica Biosciences and served as Chief Scientist at NeuronZ, both New Zealand–based biotechnology firms. From 1990 to 1997, Dr. Clark was Consultant and Senior Scientist in the research department at Genentech, where he led pre-clinical development and guided key research programs for GH secretagogues, GH, IGF-1 and small molecule IGFs. Dr. Clark spent several years as Professor of Endocrinology at the University of Auckland. He is an inventor on over 40 issued U.S. patents and has been published in more than 100 scientific journals. |
|
| |
 Ajay Bansal, Executive Vice President and Chief Financial Officer
Prior to joining the company, Mr. Bansal was employed by Nektar Therapeutics, where he served as Vice President of Finance and Administration and Chief Financial Officer from February 2003 to January 2006. From July 2002 until joining Nektar, Mr. Bansal served as Director of Operations Analysis at Capital One Financial. From August 1998 to June 2002, Mr. Bansal was at Mehta Partners LLC, a financial advisory firm where he was named partner in January 2000. Prior to joining Mehta Partners, Mr. Bansal spent more than 10 years in management roles at Novartis and in consulting at Arthur D. Little, Inc., McKinsey & Company, Inc., and ZS Associates. Mr. Bansal holds a Bachelor of Technology degree from the Indian Institute of Technology (Delhi), an M.S. in Operations Management from Northwestern University, and an M.B.A. from Northwestern University. |
|
| |
 Stephen N. Rosenfield, Executive Vice President of Legal Affairs, General Counsel and Secretary
Prior to joining Tercica, from 2000 to 2004, Mr. Rosenfield served as Executive Vice President of Legal Affairs, general counsel and Secretary of InterMune, Inc. During his tenure at InterMune, Mr. Rosenfield was instrumental in building and managing the legal department. From 1996 to 2000, Mr. Rosenfield was an attorney at Cooley Godward LLP where he was outside counsel for biotechnology and technology clients. Mr. Rosenfield's earlier legal counsel experience was in litigation at Coblentz, Patch, Duffy and Bass from 1992 to 1996. He earned his Juris Doctor degree from Northeastern University School of Law and received his Bachelors of Science degree from Hofstra University. |
|
| |
 Andrew Grethlein, Ph.D., Senior Vice President, Pharmaceutical Operations
Prior to joining Tercica in 2003, Dr. Grethlein served at Athena Neurosciences and Élan, most recently as Senior Director and site head, South San Francisco Pharmaceutical Operations. In this capacity, Dr. Grethlein held responsibility for manufacturing operations for Myobloc® (Botulinum Toxin Type B) Injectable Solution. While at Athena and Élan, Dr. Grethlein held positions of responsibility for clinical manufacturing, facility design, construction, and start-up, and manufacturing operations in support of product licensure in the United States and the EU. He also served in various engineering capacities for non-profit research and business development corporation Michigan Biotechnology Institute and its subsidiary Grand River Technologies, Inc. Dr. Grethlein earned his B.S. in Biology from Bates College and an M.S. and Ph.D. in Chemical Engineering from Michigan State University. |
|
| |
 Thorsten von Stein, M.D., Ph.D., Senior Vice President and Chief Medical Officer
Dr. von Stein joined Tercica from NeurogesX where he served most recently as Chief Medical Officer, and previously as Vice President, Clinical Development. Prior to his tenure at NeurogesX, from 1994 to 2001, Dr. von Stein held positions of increasing responsibility in medical research, global clinical development, and project management for Roche Palo Alto and F. Hoffmann-La Roche AG in Basel, Switzerland. Dr. von Stein received his M.D. from Munich University, Germany, and his Ph.D. in Computer Science from the University of Hamburg, Germany. |
|
| |
 Susan Wong, Vice President, Finance and Chief Accounting Officer
Prior to joining Tercica, Ms. Wong was an independent financial services consultant and prior to that was Senior Vice President and Corporate Controller at InnoVentry Corp., a privately held provider of fee-based financial services. She also served as Vice President and Corporate Controller at Ocular Sciences, Inc., a publicly held manufacturer and distributor of soft contact lenses. Prior to Ocular Sciences, Ms. Wong served as Director of Corporate Accounting and Financial Reporting, Planning & Analysis at Vanstar, Inc. Ms. Wong held various positions in the Audit group at PricewaterhouseCoopers LLP from August 1985 to August 1989. Ms. Wong is a Certified Public Accountant, and received her B.S. degree in finance and accounting from University of California at Berkeley. |
|
| |
 William Yates, Vice President, Human Resources and Information Technology
Prior to joining Tercica, Mr. Yates served as Senior Director, Information Technology (IT) at Intermune, Inc., a biopharmaceutical company based in Brisbane, California. At Intermune, he provided strategic IT direction and was responsible for the complete build-out of the company's IT function. Prior to his tenure at Intermune, Mr. Yates spent six years in IT management roles at Novartis and Sandoz in Canada and in Basel, Switzerland. He obtained a Bachelor of Science degree in Computer Science/Economics at Trent University in Ontario, Canada. |
|
|
